SCHEMBL266559

SCHEMBL266559

CCOCCN(CCOCC)Cc1ccc(C(=O)Nc2ccc(Br)cc2C(=O)N/N=C/c2cccc(OC)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
NPSR1 Q6W5P4 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MAPT P10636 6/20 0.47
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
KDM4E B2RXH2 3/20 0.47
THRB P10828 1/20 0.47
PKM P14618 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
SPHK2 Q9NRA0 2/20 0.44
SPHK1 Q9NYA1 2/20 0.44
ALOX12 P18054 1/20 0.44
POLB P06746 2/20 0.43
PLEC Q15149 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266560 1.00 HPGD (0.54) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL267081 0.92 MAPT (0.56) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL267080 0.92 MAPT (0.56) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL267515 0.91 SMN1; SMN2 (0.53) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL267514 0.91 SMN1; SMN2 (0.53) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL267454 0.90 SLC34A2 (0.44) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL267453 0.90 SLC34A2 (0.44) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL266908 0.87 HPGD (0.53) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL266909 0.87 HPGD (0.53) HPGDMEN1KMT2ANPSR1L3MBTL1
SCHEMBL267698 0.87 MEN1 (0.55) HPGDMEN1KMT2ANPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 HPGD 2509/4885MEN1 1194/4885KMT2A 4564/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 HPGD 2407/4885MEN1 1638/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.